Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
766.131.1%
QQQ
716.951.17%
BTC/USD
77574.091.3586%
DIA
526.881.18%
GLD
400.401.02%
TLT
81.060.35%

ORIC Pharmaceuticals Inc

ORICNASDAQ
Trade with Public
Trade with Public
$12.10
0.030.25%
Last update: Sep 11, 1:26 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

ORIC Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ORIC Pharmaceuticals (ORIC).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$20Upside to Avg. PT+62.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 10, 2026HC Wainwright & Co.Robert BurnsPT RaiseBuy$25→$27
Jun 8, 2026HC Wainwright & Co.Robert BurnsMaintainedBuy$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $17

Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $20 to $17.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved